InflaMix Identifies CAR-T Recipients with a Preinfusion Inflammatory Profile Indicative of High Risk for CAR-T Treatment Failure By Ogkologos - May 5, 2025 147 0 Facebook Twitter Google+ Pinterest WhatsApp A valuable tool for point-of-care clinical decision-making in patients with non-Hodgkin lymphoma Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Gemcitabine Intravesical System for Non-Muscle Invasive Bladder Cancer ESMO Calls for Robust EU Taxation of Tobacco Products, Aiming to Prevent Cancers Attributable to Tobacco Use EMA Recommends Granting a Marketing Authorisation for Biosimilar Pegfilgrastim MOST POPULAR Singer Surprises 6-Year-Old Fan Who Beat Cancer With Trip To Disney January 10, 2022 Man Gives Up His First-Class Seat For 88-Year-Old Woman, Makes Her... November 16, 2021 From smouldering ash to a gleaming temple for cancer research: The... April 26, 2023 ASCO20 Virtual Research Round Up Podcast: Breast Cancer, Sarcoma, and Supportive... July 21, 2020 Load more HOT NEWS ESMO Breast Cancer 2024, 15-17 May, Berlin, Germany Family Brings Joy & Raises Money With Their Extravagant Christmas Light... Blood Test Accurately Detects Early-Stage Pancreatic Cancer How serendipity sent this oncologist in search of a cure for...
